(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
29 January 2009 (29.01.2009)

PCT

(10) International Publication Number
WO 2009/014534 A1

(51) International Patent Classification:
A61K 9/28 (2006.01) *A61K 31/00* (2006.01)

(21) International Application Number:
PCT/US2007/073957

(22) International Filing Date: 20 July 2007 (20.07.2007)

(25) Filing Language: English

(26) Publication Language: English

(71) Applicants *(for all designated States except US)*: **ABBOTT GMBH & CO. KG** [DE/DE]; Max-Planck-Ring 2, 65205 Wiesbaden (DE). **LIU** [CN/US]; 1287 Derby Lane, Mundelein, Illinois 60060 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **ROSENBERG, Joerg** [DE/DE]; Bruchstrasse 29, 67158 Ellerstadt (DE). **WOEHRLE, Gerd** [DE/DE]; Seestrasse 58, 69214 Eppelheim (DE). **KESSLER, Thomas Y.** [DE/DE]; Mutterstadter Str. 113, 67105 Schifferstadt (DE). **BREITENBACH, Joerg** [DE/DE]; Hans-Sachs-Ring 959, 68199 Mannheim (DE). **DURAK, Salih** [DE/DE]; Hemshofstrasse 70, 67063 Ludwigshafen (DE). **RICHTER, Friedrich W.** [DE/US]; 175 Margate Court, Lake Bluff, Illinois 60044 (US). **DUTTA, Sandeep** [DE/US]; 7303 Clem Drive, Gurnee, Illinois 60031 (US).

(74) Agent: **SRIVASTAVA, Sonali S.**; Abbott Laboratories, Dept. 0377, Bldg. AP6A-1A, 100 Abbott Park Road, Abbott Park, Illinois 60064-6008 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

WO 2009/014534 A1

(54) Title: FORMULATIONS OF NONOPIOID AND CONFINED OPIOID ANALGESICS

(57) Abstract: The preferred exemplary embodiments in the present application provide formulations and methods for the delivery of drugs, particularly drugs of abuse, having an abuse-relevant drug substantially confined in the core and a non-abuse relevant drug in a non-core region. These formulations have reduced potential for abuse. In the formulation, preferably the abuse relevant drug is an opioid and the non-abuse relevant drug is acetaminophen or ibuprofen. More preferably, the opioid is hydrocodone, and the non-abuse relevant analgesic is acetaminophen. In certain preferred embodiments, the dosage forms are characterized by resistance to solvent extraction; tampering, crushing or grinding. Certain embodiments of the inventions provide dosage forms that provide an initial burst of release of drug followed by a prolonged period of controllable drug release.